share_log

Pfizer | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC(4.96%)

Pfizer | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC(4.96%)

辉瑞 | SC 13G/A：超过5%持股股东披露文件(修正)-PFIZER INC(4.96%)
SEC announcement ·  03/15 19:50
牛牛AI助手已提取核心信息
Pfizer Inc., a pharmaceutical giant incorporated in Delaware, has filed an exit filing with the United States Securities and Exchange Commission (SEC) on January 29, 2024, indicating that it no longer holds more than 5% of Tourmaline Bio, Inc.'s common stock. The filing, made under Rule 13d-1(c) of the Securities Exchange Act of 1934, shows that Pfizer Inc. beneficially owns 1,272,214 shares of Tourmaline Bio's common stock, which represents 4.96% of the company's class of securities. This percentage is based on 25,645,262 shares of common stock outstanding as disclosed by Tourmaline Bio in its prospectus supplement filed on January 26, 2024. The address of Pfizer's principal business office is 66 Hudson Boulevard East, New York, NY, and the CUSIP number for the securities is 89157D 105. Pfizer's filing confirms that the shares were not acquired for the purpose of changing or influencing the control of Tourmaline Bio and were not held in connection with any transaction having that purpose or effect.
Pfizer Inc., a pharmaceutical giant incorporated in Delaware, has filed an exit filing with the United States Securities and Exchange Commission (SEC) on January 29, 2024, indicating that it no longer holds more than 5% of Tourmaline Bio, Inc.'s common stock. The filing, made under Rule 13d-1(c) of the Securities Exchange Act of 1934, shows that Pfizer Inc. beneficially owns 1,272,214 shares of Tourmaline Bio's common stock, which represents 4.96% of the company's class of securities. This percentage is based on 25,645,262 shares of common stock outstanding as disclosed by Tourmaline Bio in its prospectus supplement filed on January 26, 2024. The address of Pfizer's principal business office is 66 Hudson Boulevard East, New York, NY, and the CUSIP number for the securities is 89157D 105. Pfizer's filing confirms that the shares were not acquired for the purpose of changing or influencing the control of Tourmaline Bio and were not held in connection with any transaction having that purpose or effect.
辉瑞公司是一家在特拉华州注册成立的制药巨头，已于2024年1月29日向美国证券交易委员会（SEC）提交了退出申请，表示其持有的不再超过Tourmaline Bio, Inc.5％的股份。”s 普通股。该文件是根据1934年《证券交易法》第13d-1（c）条提交的，显示辉瑞公司实益拥有Tourmaline Bio普通股的1,272,214股，占该公司证券类别的4.96％。该百分比基于Tourmaline Bio在2024年1月26日提交的招股说明书补充文件中披露的25,645,262股已发行普通股。辉瑞主要营业办公室的地址是纽约州纽约哈德逊大道东66号，证券的CUSIP号码为89157D 105。辉瑞的文件证实，收购这些股份不是为了改变或影响Tourmaline Bio的控制权，也不是与任何具有该目的或效果的交易有关而持有的。
辉瑞公司是一家在特拉华州注册成立的制药巨头，已于2024年1月29日向美国证券交易委员会（SEC）提交了退出申请，表示其持有的不再超过Tourmaline Bio, Inc.5％的股份。”s 普通股。该文件是根据1934年《证券交易法》第13d-1（c）条提交的，显示辉瑞公司实益拥有Tourmaline Bio普通股的1,272,214股，占该公司证券类别的4.96％。该百分比基于Tourmaline Bio在2024年1月26日提交的招股说明书补充文件中披露的25,645,262股已发行普通股。辉瑞主要营业办公室的地址是纽约州纽约哈德逊大道东66号，证券的CUSIP号码为89157D 105。辉瑞的文件证实，收购这些股份不是为了改变或影响Tourmaline Bio的控制权，也不是与任何具有该目的或效果的交易有关而持有的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。